Academic Journal
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
| العنوان: | Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. |
|---|---|
| المؤلفون: | Garbe, C., Keim, U., Amaral, T., Berking, C., Eigentler, T.K., Flatz, L., Gesierich, A., Leiter, U., Stadler, R., Sunderkötter, C., Tüting, T., Utikal, J., Wollina, U., Zimmer, L., Zouboulis, C.C., Ascierto, P.A., Eggermont, AMM, Grob, J.J., Hauschild, A., Sekulovic, L.K., Long, G.V., Luke, J.J., Michielin, O., Peris, K., Schadendorf, D., Kirkwood, J.M., Lorigan, P.C. |
| المساهمون: | Central Malignant Melanoma Registry (CMMR) |
| المصدر: | Journal of clinical oncology, vol. 40, no. 32, pp. 3741-3749 |
| سنة النشر: | 2022 |
| المجموعة: | Université de Lausanne (UNIL): Serval - Serveur académique lausannois |
| مصطلحات موضوعية: | Humans, Neoplasm Staging, Skin Neoplasms/drug therapy, Melanoma/drug therapy, Prognosis, Adjuvants, Immunologic/therapeutic use |
| الوصف: | The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma. The Central Malignant Melanoma Registry (CMMR) in Germany evaluated 17,544 patients with a primary diagnosis of stage I and II melanoma from 2000 to 2015. The exploratory cohort consisted of 6,725 patients from the Center for Dermato-Oncology at the University of Tübingen, and the confirmatory cohort consisted of 10,819 patients from 11 other German centers. Survival outcomes were compared with published American Joint Committee on Cancer version 8 (AJCCv8) stage I and II survival data. For the two CMMR cohorts in stage IA compared with the AJCCv8 cohort, melanoma-specific survival rates at 10 years were 95.1%-95.6% versus 98%; 89.7%-90.9% versus 94% in stage IB; 80.7%-83.1% versus 88% in stage IIA; 72.0%-79.9% versus 82% in stage IIB; and 57.6%-64.7% versus 75% in stage IIC, respectively. Recurrence rates were approximately twice as high as melanoma-specific mortality rates in stages IA-IIA. The melanoma-specific survival rates in the two CMMR cohorts across stages I and II are less favorable than published in AJCCv8. This has important implications for the consideration of adjuvant treatment in this population. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/35709414; info:eu-repo/semantics/altIdentifier/eissn/1527-7755; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_552F42A6F0C70; https://serval.unil.ch/notice/serval:BIB_552F42A6F0C7; https://serval.unil.ch/resource/serval:BIB_552F42A6F0C7.P001/REF.pdf |
| DOI: | 10.1200/JCO.22.00202 |
| الاتاحة: | https://serval.unil.ch/notice/serval:BIB_552F42A6F0C7 https://doi.org/10.1200/JCO.22.00202 https://serval.unil.ch/resource/serval:BIB_552F42A6F0C7.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_552F42A6F0C70 |
| Rights: | info:eu-repo/semantics/openAccess ; CC BY-NC-ND 4.0 ; https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: | edsbas.B85B785B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1200/JCO.22.00202 |
|---|